moomoo ID:NaN
Log Out
Log in to access Online Inquiry

Protagenic Therapeutics (OTCMKTS:PTIX) Stock Price Passes Below 200-Day Moving Average of $0.80

Defense World ·  {{timeTz}}

Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating)'s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.80 and traded as low as $0.62. Protagenic Therapeutics shares last traded at $0.65, with a volume of 61,694 shares traded.

Protagenic Therapeutics Stock Performance

The stock has a fifty day simple moving average of $0.68 and a two-hundred day simple moving average of $0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.47 and a quick ratio of 19.47.

Get Protagenic Therapeutics alerts:

Institutional Investors Weigh In On Protagenic Therapeutics

An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned about 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent reporting period. 11.09% of the stock is currently owned by institutional investors and hedge funds.

About Protagenic Therapeutics

(Get Rating)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

Featured Articles

  • Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
  • MarketBeat Podcast: Fantasy Football Strategy With Your Stock Portfolio
  • Should You Buy These Copper Stocks Ahead Of Monster Demand?
  • Three Industrial Stocks That Can Weather a Stormy Recession
  • Bed Bath & Beyond Meat: Is BYND the Next Big Short Squeeze?
  • Denbury Rises On Rumor Of A Sale, But Lags Other Energy Names

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.